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Abstract
Introduction: In the current mobility and globalization context, there is a growing need to identify potential
changes on the pattern of diseases in the European Union (EU)/European Economic Area (EEA) and provide
accurate diagnosis and treatment for the population. The pattern of rare communicable diseases that can affect
people returning to EU/EEA from travel abroad, visiting EU/EEA or establishing in the EU/EEA is of special relevance.
The objective of this manuscript is to give an overview about the EURaDMoG study and discuss the feasibility of
establishing a European network on rare communicable diseases and other rare conditions linked to mobility and
globalization.
Methods: We undertook a three-steps process where we first conducted a narrative review to estimate the
prevalence and incidence and to list rare communicable and non-communicable diseases linked to mobility and
globalization in the EU/EEA; second, we organized an international consultation workshop with experts in the
diseases previously selected; and finally, the feasibility study analysed how successful a European expert network on
rare diseases linked to mobility and globalization focused on health care provision would be, accounting for
different operational and also sustainability criteria.
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Results: First, considering the areas or topics that the network should cover, it was concluded that communicable
and non-communicable rare diseases linked to mobility and globalization should be differentiated. Second, since all
non-communicable rare diseases linked to mobility and globalization identified are already covered by different
European Reference Networks (ERNs), there is no need for them to be included in a new European network. Three
scenarios were considered for establishing a potential European network for rare communicable diseases linked to
Mobility and Globalisation with a focus on Health Care provision: 1) To maintain the current situation “Status Quo”
scenario; 2) to create a specific European expert network (EEN) on rare communicable diseases linked to mobility
and globalisation; 3) to develop a new ERN on communicable rare diseases linked to mobility and globalisation.
Conclusions: Since the focus is the provision of health care, an ERN could have the potential to better boost the
quality of care being facilitated by technological tools and online platforms that permit the safe and ethically
acceptable exchange of data. However, this potential new network should not eclipse current existing networks
and they should be complementary.
Keywords: Rare diseases, Mobility, Globalisation, Imported diseases, Communicable diseases, Rare infections
Background
Population movements have had a major impact on dis-
ease epidemiology and public health [1]. There is a
growing need to provide health care for “rare” diseases
that are related to this context. The European Union
(EU) /European Economic Area (EEA) countries are
tackling new emerging diseases not endemic in EU
countries [2] which are not considered rare diseases at
the world-wide level, but which are rare conditions in
Europe according to the definition of rare diseases from
the European Commission (EC) [3] or are emerging due
to climate change.
Such a definition of rare diseases was adopted by the
Community Action Programme on rare diseases 1999–
2003 as those life-threatening or chronically debilitating
diseases presenting a prevalence less than 5 per 10,000
people in the EU [4].
In addition to the limited number of patients, rare dis-
eases are characterised by by scarce knowledge and ex-
pertise, single them out as a distinctive domain of very
high European added value [5]. European cooperation
can help to ensure that scarce knowledge can be shared
and resources combined as efficiently as possible, in
order to tackle rare diseases effectively across the EU/
EEA as a whole [4]. Classically, most rare diseases are
genetic disorders, that is, non-infectious inherited condi-
tions [6], but there are also other rare diseases like rare
cancers, auto-immune diseases, toxic disorders and com-
municable diseases. Imported diseases which are not fa-
miliar to European health professionals, have recently
been recognized as a new challenge as they have been
found to be prevalent only in mobile populations coming
from tropical countries [7]. Although most migrants and
newly arriving refugees do not pose a special challenge
for the autochthonous population in terms of commu-
nicable diseases risk [8], they are disproportionately af-
fected by infectious diseases that at some point may
have an impact on the health system (critical care for
immunosuppressed migrant patients, transplant pro-
grams ...) [9]. Therefore, the risk of communicable dis-
eases (CD) is in accordance to the country of origin and/
or transit of migrants and refugees because prevalence
rates and burden of CD differ considerably by country
[10]. In this regard, additional work is needed to im-
prove the knowledge gaps among different categories of
health professionals [9].
In the same way, the increase of global mobility related
to tourism or trade has increased the risks of rare com-
municable diseases in travellers, particularly vector
borne diseases [11]. During the last century, invasive
mosquito species have become widely established across
Europe [12]. Although subsequent transmission and out-
breaks of unfamiliar diseases such as Chikungunya and
Dengue are in part due to increased globalisation, with
intercontinental air travel and global shipping transport
[11], changes in vector distributions are also being
driven by climatic changes and changes in land use, in-
frastructure, and the environment [13].
Regarding rare CD, health professionals often lack the
necessary skills to correctly identify and treat unfamiliar
pathologies, due to their low prevalence in the countries
where they are working or because they are newly emer-
ging diseases [14]. In the same way, the increase in glo-
bal mobility for tourism or trade poses similar risks of
rare diseases in travellers, often implying a particular
challenge for diagnosis and management [11]. It is also
worth mentioning the effect of climate change on vector
borne diseases [15]. Sharing medical knowledge and ex-
pertise is an important strategy for developing the com-
petencies and skills of health professionals to address
patients’ needs and support change in health service
provision [16, 17]. It is clear that the focus here is the
diagnosis and treatment, not the epidemiological surveil-
lance of the diseases.
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On the other hand, non-communicable diseases
(NCD) may also represent a challenge in mobile popula-
tions, particularly in migrants. Haemoglobin disorders
such as thalassemia or sickle cell disease (SCD) are
inherited disorders whose frequency varies by ethnic
group [18]. Due to population movements, the sickle cell
trait has been spread to other places such as the Middle
East and Southern Europe [19], where thalassemia has
also been endemic until now, also due to the historical
endemic presence of malaria until recently. Most rare
non communicable diseases are already covered by the
existing ERN [20].
The objective of this study was to evaluate the feasibil-
ity of a European expert network on rare diseases linked
to mobility and globalization focused on Health Care
provision.
The EURaDMoG feasibility study
This study analysed how successfully a European expert
network on rare diseases linked to mobility and
globalization focused on Health Care provision would be,
accounting for different factors or criteria that will be out-
lined. Through this study, potential positive and negative
outcomes of the network have been envisaged. All these
factors have been separately assessed considering different
scenarios and have been evaluated based on the results of
a consultation workshop, with a combined three-step ap-
proach: [1] conducting a comprehensive review, a [2] con-
sultation workshop, [3] an overall feasibility assessment.
The main results are described hereunder.
1. A comprehensive review was carried out to assess
epidemiological, diagnostic and treatment aspects of
rare diseases (both communicable and non-
communicable) linked to Mobility and Globalisation
and to elaborate a list of rare diseases linked to mo-
bility and globalisation.
The primary objective was to assess which rare dis-
eases (according to the EC definition of rare disease)
should be covered by a potential expert European net-
work of rare disease linked to mobility and Globalisa-
tion, to review their prevalence and/or incidence in EU/
EEA countries as well as their epidemiological profile.
For that purpose, first a narrative review of the litera-
ture has been conducted to explore which rare diseases
(both communicable and non-communicable) in EU/
EEA countries are linked to mobility and Globalization.
For communicable diseases, first, we reviewed the
Orphanet list if rare disease [21], selecting those that are
associated with mobility and globalisation. This relation-
ship was established either because these diseases are
more frequent in mobile populations (migrants and trav-
ellers) irrespective of whether they are imported diseases
or not, or because of the risk of being introduced /rein-
troduced or of changing their epidemiology in EU/EEA
countries due to environmental factors such as climate
change. We also conducted an online survey with ex-
perts in CD to agree the preliminary of CD identified.
The survey was distributed among European network
targeting most of the diseases identified in the list The
European Network for Tropical Medicine and Travel
Health (TROPNET) [22], the European Travel and
Tropical Medicine Network (EUROTRAVNET) [23] and
the European Expert laboratory network for emerging
viral diseases (EVDLABNET) [24].
Thereafter, the prevalence /incidence of these disor-
ders were comprehensively reviewed through a narrative
review of the literature [25]. Concerning CD, we have
identified more than 130 infections that could be consid-
ered “rare diseases” in EU/EEA countries and that are
linked to mobility and globalisation (See Table 1).. In
addition, many studies also highlight that most of these
diseases do not have appropriate and widely available
diagnostic techniques and treatments.
Concerning NCD, we have comprehensively reviewed the
literature to assess the association between traditional rare
diseases (non CD) with mobility and globalization in EU/
EEA countries [25]. The online survey was also conducted
with experts belonging to the 24 European Reference Net-
works (ERN) in the EU/EEA to agree the preliminary of
rare non-CD identified. Some autosomal recessive disorders
have been particularly found to be associated with mobility
and globalization, in part because co-sanguinity is more fre-
quent in certain migrant populations.
Other results of the review also showed that most
studies were conducted in highly specialized units (par-
ticularly in Tropical diseases), suggesting a lack of know-
ledge among other health professionals regarding
imported diseases. It was also concluded that the areas
of expertise are quite different between rare NCD and
CD. In the particular case of CD, a high expertise is re-
quired in some areas of infectious disease, particularly in
Tropical Medicine, imported diseases and also tick-
borne diseases. Due to changes in the epidemiology of
rare CD (e.g. West Nile virus or Chikungunya), a net-
work including experts from countries where these dis-
eases are less rare would be helpful to clinicians working
in countries where cases are rarely diagnosed. In this re-
gard, although a list of CD has been proposed (See Add-
itional file 1), the list should remain open to be updated
in case new diseases are emerging. All these challenges
should be considered when designing appropriate strat-
egies to improve the health care provision related to
these diseases in people living in EU/EEA countries.
2. A consultation Workshop was conducted on the
“Assessment of a European Expert Network on
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Table 1 List of rare communicable diseases linked to mobility and globalisation identified throughout the euradmog study




Endemic typhus, Murine typhus /flea-borne typhus Rickettsia typhi
Epidemic typhus Rickettsia prowazekii
Mediterranean spotted fever Rickettsia conorii
Rickettsialpox Rickettsia akari
Scrub typhus, Tsutsugamushi disease Orientia tsutsugamushi
Rocky mountain spotted fever Rickettsia rickettsii
African tick typhus Rickettsia africae
Relapsing fever Borrelia recurrentis
Lyme disease Borrelia burgdoferi





Granuloma inguinale- Donovanosis Klebsiella granulomatis
Actinomycosis Actinomyces israelii
Treponema infections Yaws Treponema pallidum pertenue
Buruli ulcer Mycobacterium ulcerans
Hansen’s disease / Leprosy Mycobacterium leprae
Leptospirosis Leptospira interrogans
Bartonellosis, Oroya fever, Carrion disease Bartonella bacilliformis
Bartonellosis, Trenchs fever Bartonella quintana
Brucellosis, Malta fever Brucella spp.
Melioidosis Burkholderia pseudomallei
Paratyphoid fever Salmonella enterica serotype Paratyphi
Typhoid fever Salmonella enterica serotype Typhi
Rheumatic fever Streptococcus pyogenes
Q fever, Nine mile fever, Quadrilateral fever, Query fever Coxiella burnetii








Chromomycosis/Chromoblastomycosis Fonsecaea pedrosoi, Phialophora verrucosa and Cladophialophora
carrionii
Madura foot /Eumycetoma Madurella mycetomatis
Sporotrichosis Sporothrix schenckii
Paracoccidioidomycosis Paracoccidioides brasiliensis
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Table 1 List of rare communicable diseases linked to mobility and globalisation identified throughout the euradmog study
(Continued)
DISEASE related keywords MICROORGANISM related keywords




Cystic echinococcosis, Echinococcosis Echinococcus granulosus
Alveolar echinococcosis Echinococcus multilocularis
Ancylostomiasis /Ankylostomiasis Ancylostoma duodenale /Necator americanus
Angiostrongyliasis Angiostrongylus cantonensis
Strongyloidiasis, Anguilluliasis Strongyloides stercoralis
Anisakiasis Anisakis spp.
Ascariasis Ascaris lumbricoides
Bilharziasis, Schistosomiasis Schistosoma spp.
Clonorchiasis Clonorchis sinensis
Opisthorchiasis Opisthorchis viverrini




Distomatosis Other trematodes-Heterophyes heterophyes, Metagonimus spp.














Acanthamoeba infection, Keratitis Acanthamoeba spp.
African trypanosomiasis, Sleeping sickness Trypanosoma brucei
Amebiasis Entamoeba histolytica
Amebic meningoencephalitis Naegleria fowleri
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Table 1 List of rare communicable diseases linked to mobility and globalisation identified throughout the euradmog study
(Continued)
DISEASE related keywords MICROORGANISM related keywords
Malaria Plasmodium spp.
Sarcocystosis, Sarcosporidiosis Sarcocystis hominis
VIRAL INFECTIONS
Avian flu Avian influenza
Brazilian haemorrhagic fever Sabia virus
California encephalitis California encephalitis virus
Chapare haemorrhagic fever Chapare virus
Chikungunya Chikungunya virus
Colorado tick-borne disease, Mountain fever, American mountain fever, Mountain
tick fever-
Colorado tick fever (CTF)
Crimea-Congo haemorrhagic fever CCHF virus
Dengue fever Dengue virus
Ebola Ebola virus
Hantavirosis, Haemorrhagic fever-renal syndrome Hantavirus
Hepatitis D Hepatitis D virus
Hepatitis E Hepatitis E virus
Herpes B infection, B virus infection Herpesvirus simiae, monkey B virus
Tropical spastic paraparesis Human T-lymphotropic virus 1 (HTLV-1)
Japanese encephalitis Japanese encephalitis virus (JEV)
Junin haemorrhagic fever, Argentine haemorrhagic fever Junin virus
Kyasanur haemorrhagic fever, Kyasanur forest disease, Monkey fever, Monkey
disease
KFD virus (KFDV)
La Crosse encephalitis La Crosse virus (LACV)
Lassa haemorrhagic fever Lassa virus
Lujo haemorrhagic fever, Zambian haemorrhagic fever Lujo virus
Machupo haemorrhagic fever Machupo virus (MACV)
Marburg haemorrhagic fever /Marburg virus disease Marburg virus
Nipah encephalitis, Nipah fever /Nipah virus disease Nipah virus
Omsk haemorrhagic fever Omsk haemorrhagic fever virus (OHFV)
Poliomyelitis, Poliomyelitis in patients with immunodeficiency deemed at risk Poliovirus
Rabies Rabies virus
Rift valley fever Rift valley fever (RVF) virus
Saint Louis encephalitis Saint Louis encephalitis (SLE) virus
Tick-borne encephalitis Tick-borne encephalitis (TBE) virus
Venezuelan haemorrhagic fever Guanarito virus
Western equine encephalitis, Western equine encephalomyelitis Western equine encephalitis (WEE) virus
West-Nile encephalitis, West-Nile fever West-Nile virus (WNV)
Yellow fever Yellow fever virus
Zika virus disease Zika virus
Middle East respiratory syndrome coronavirus MERS-CoV
OTHER CONDITIONS
Tick paralysis Tick
Cutaneous myiasis Dermatobia hominis, Cordylobia anthropophaga
African iron overload
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communicable diseases and other rare pathologies
in the context of Mobility and Globalization”.
Participants of the online survey and belonging to
the networks TROPNET, EUROTRAVNET, EVDL
ABNET and the existing 24 ERN in the EU/EEA
were invited to participate to have a minimum of
two health care professionals per country in the EU
(the countries participating the study) with
expertise on rare diseases linked to mobility and
globalisation. Whenever possible, they were selected
as one member with expertise in rare-CD (imported
or vector-borne diseases) and the other one with
expertise in rare NCD. The workshop was finally
attended by 57 people (health professionals with ex-
pertise in rare CD and rare NCDs from EU coun-
tries, Norway and from the EC) from 26 countries.
In the workshop, besides recognising the growing need
to attend rare diseases related to mobility and
globalization, the participants almost unanimously
agreed to differentiate CD and NCD. The latter are
already covered by different ERNs and should not be in-
cluded in a new network. Concerning the benefit of a
having a network on rare CD with a focus on Health
Care provision, several arguments were raised:.
 To find spaces to further enable the discussion of
clinical cases; and discussion between clinical and
laboratory experts (e.g. in terms of test results, how
to deal with false-positives etc.); and also as a meet-
ing point of needs, feedbacks and expertise for
Health Care Providers (HCPs) and the external en-
vironment (other networks, authorities, health sys-
tems, private sectors, etc.). This may reduce
inappropriate practice variation.
 To promote the access to complex diagnostic tests
and also to drugs for neglected diseases in order to
reduce inequalities in health care.
 To give better advice to governments, or to be
linking with the European regulatory bodies to
improve access to orphan drugs; and to act as a
promoter of harmonized strategies and actions (e.g.
to improve the standards of screening strategies of
imported diseases across Europe for blood or
transplant donors, pregnant women or
immunosuppressed individuals)
 To supervise and improve online available data and
the registry of diseases that are not currently under
surveillance, promoting the access to reliable
information on new developments.
 To enhance translation of research into practice
by reinforcing research and epidemiological
surveillance and improve knowledge for
physicians, healthcare providers, patients and
families.
 To promote clinical evidence-based guidelines on
imported diseases based on a robust methodology
and exchange of healthcare professionals as well as
training and education activities (e.g. webinars, e-
learning courses or summer schools among others)
would be a countless benefit.
 Cross-linking mechanisms with other ERNs should
be promoted. Few examples of the types of
collaborations in this regard include among others:
(i) To discuss and interact in some diseases that
require a multidisciplinary approach (e.g.
cysticercosis may require a follow-up from an
Table 1 List of rare communicable diseases linked to mobility and globalisation identified throughout the euradmog study
(Continued)
DISEASE related keywords MICROORGANISM related keywords
Ciguatera fish poisoning
Tropical calcific chronic pancreatitis Tropical pancreatitis
Tropical pancreatic diabetes
Tropical endomyocardial fibrosis (TEF)
Acquired Creutzfeldt-Jakob disease prion disease
Hyperreactive malarial splenomegaly
Genital female mutilation
Severe fever with thrombocytopenia syndrome
INFECTIONS WITH PARTICULAR ASPECTS TO BE CONSIDERED
Giardiasis Giardia duodenalis
Shiga-like toxin-associated HUS E.coli (O157)
Tuberculosis Mycobacterium tuberculosis
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Infectious diseases specialist but also from a
Neurologist);
(ii) To discuss with experts belonging to other ERNs
the specific problems and requirements of the
growing number of travellers to tropical
countries who are affected by chronic diseases,
e.g. providing specific advice about the drug
interaction with malaria chemoprophylaxis or
about the contraindications of lived-attenuated
vaccine.
3. The feasibility assessment was aimed at analysing
how successful a European expert network on rare
communicable diseases linked to mobility and
globalization focused on Health Care provision
would be based on the results of the review and the
Consultation Workshop, considering which are the
options for building the network.
The options and conditions of creating a European ex-
pert network for rare CD linked to Mobility and Global-
isation (for diagnosis and treatment) were evaluated,
considering three different scenarios:
1) “Status Quo” scenario, where current European
networks identified would be enhanced but no new
network would be built.
2) To create a specific European expert network
(EEN) on rare CD linked to mobility and
globalisation with the governance and structure to
be defined.
3) To develop a new European Reference Network
(ERN) on CD linked to mobility and globalisation in
the same way as the current ERNs.
To do the assessment, the operational criteria of a po-
tential network were developed and adapted from the
criteria established by the European Commission for
ERN (Operational Criteria for the Assessment of Net-
works) [26]. They were:
1) The establishment, including objectives and
activities covered in the network, regulations of the
network that should comply with EU regulations,
but also the criteria and conditions to constitute the
network.
2) The provision of highly specialized care in the areas
of diagnosis, treatment and follow-up. This criterion
included an assessment of the thematic areas and
diseases covered by the network, the capability of
improving health care provision and the capacity to
create data registries,
3) The governance coordination and management,
including the establishment of a board of the
network, the coordinator, the criteria that newly
formed HCP wishing to join an ERN must meet
and the involvement of patients’ associations.
4) The ability to promote a good quality and safe
patient care by fostering timely and pertinent
diagnosis, treatment, follow-up and management
across the Network.
5) Continuous education, training and development,
including the creation or participation in evidence-
based guidelines/recommendations, the sharing of
knowledge and technologies and other training ac-
tivities or education materials.
6) The capacity of conducting and collaborating in
research activities (e.g. clinical trials) and the
possibility of establishing shared registries and
databases aiming to integrate existing resources.
7) The good practice, outcome measures and quality
control measures for the network.
8) The multidisciplinary approach.
9) The capacity of establishing further networking and
collaborations including the assessment of the
added value that the network could bring to health
care providers, as well as to other existing networks
related to the area of expertise (e.g. other ERNs)
10) The funding sources including a management and
business plan.
11) The evaluation of the sustainability considering the
minimum of human resources required to maintain
the network; possible future funding sources; how
to ensure a roster and regular turnover of available
experts to work on the network tasks in the future;
and how will the information be made available to
wider audiences (e.g. establishment of a website,
organisation of seminars and conferences).
The detailed information about the results is summa-
rized in Table 2. The main features of each scenario
were:
1. “Status Quo” scenario: there are several existing
networks with some focus on health care provision
and patient care essentially improved through
exchange of information, continuous education and
training of health professionals. They are
TROPNET, EUROTRAVNET and EVDLABNET.
However, a proper system -according to EU data
protection regulations- has not been implemented
to share health data. There are some diseases
(particularly endemic vector-borne diseases) not
covered by these networks. All current networks
are functioning with low financial resources, most
of them private, and frequently informal and not
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Table 2 Assessment of the three options for a potential network o rare Communicable diseases linked to Mobility and Globalisation
Maintaining Status Quo Creation of a European
expert network (EEN)
Creation of a new ERN
(ERN)






There are three existing
networks.
There are members from non-
EU/EEA countries in the
networks.
They comply the minimum of
HCP and countries required.
The main goal of the
networks is not exclusively
focused on Health care
provision.
+
The EC can set the basis but
there are not currently clear
mechanisms to be supported
by EC (Health policy platform
could be one).
No clear mechanism on who
should establish the expertise
of the HCP.
A minimum of HCP identified
The HCP criteria could be
more flexible compared with
an ERN.
It may partially overlap the
focus of those existing
networks.
+ to ++
The EC and the Member
States set the basis.
The minimum of HCP
identified.
Health Care Provider status
might make difficult the
participation and enrolment
of critical centres.
It may partially overlap the
focus of those existing
networks.
The proposed number of
required number of
participants/ countries needs
to be reviewed and validated
Thematic areas
to be covered by
the network:
++
All networks are focused on
Tropical and Travel related
diseases which are rare
communicable diseases linked
to Mobility and Globalisation
(one of them with an
exclusively focus on viral
infections).
++
The network will be created
based on the findings, and
needs in terms of rare CD
linked to Mobility and
Globalisation.
++
The network will be created
based on the findings and
needs in terms of rare CD






The existing networks already
cover most of the diseases.
In TropNet and EVDLabNet,
there is not a list of diseases.
++
The diseases to be included
can be according to the
detected needs.
The list may not be a closed
list since there are potential
new public health threats for
the EU/EEA countries in the
future.
++
The diseases to be included
can be according to the
detected needs.
The list may not be a closed
list since there are potential
new public health threats for






TropNet has a forum for
discussion of clinical cases
activity although ensuring the
compliance with the EU data
protection policy is currently a
challenge.
EVDLabNet has a directory of
Laboratory capacities to
improve the access to rare
diagnostics tests.
+
This criterion may be feasible
depending on the legal basis
and cross-exchange mecha-
nisms of the network al-
though ensuring compliance
with the data EU protection
policy may be challenging.
++
This is the main guarantee of
ERN, as well as its main goal,
to ensure a better access to
highly specialized healthcare.
Data registry 0 to +
TropNet and EuroTravNet do
report number of cases yearly
as a sort of surveillance
activity but do not register
clinical cases.
The existing networks share
data, but cannot be held
responsible nor exchange
personal patient data in a
secure, safe and legally
binding environment in
compliance with the data EU
protection policy, which is
currently a challenge.
+
It is difficult to assess the
feasibility, as it will depend on
the rules, data definition and
legal framework of the
network.
This criterion may be feasible
depending on the legal basis
and cross-exchange mecha-
nisms of the network al-
though ensuring compliance
with the EU data protection
policy may be challenging.
++
This is the main guarantee of
ERN, as well as its main goal,
to ensure a better access to
highly specialized healthcare.
ERNs register clinical cases for
discussion and for a training
purpose (CPMS system).
In addition, another ERNs’
developments include online
platform to safely and
ethically share data, under the










A new network will mean
new structures and roles, but
++
The governance while
complex is aspect of the ERNs
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Table 2 Assessment of the three options for a potential network o rare Communicable diseases linked to Mobility and Globalisation
(Continued)
Maintaining Status Quo Creation of a European
expert network (EEN)
Creation of a new ERN
(ERN)





The networks might overlap
in some aspects. It is currently
foreseen to develop more
collaborations.
Members of the networks
may not necessarily be HCP.
Patients’ associations are not
involved in these networks.
it does not have to be too
complex.
It will depend on the organ




has been already established.
Patient’s associations could be
potentially involved.
Patient care + to ++
The networks do not have
guidelines to promote quality
and safe patient care.
Networks also provide
information for patients/




TropNet has available a
repository with information
on orphan drugs available in
the centres belonging to the
network.
No network has developed
ICT-tools that could be devel-
oped to provide care, access
to expertise, and support the
development, sharing and
spread of best practice. (E.g.
Telemedicine, tele-expertise or
remote consultation).
Patient care is improved
through continuous exchange
of knowledge.
Few centres from East
European countries are
involved in the networks.
+ to ++
The specialization of the
network should enable the
creation of formally accepted
professionalized guidelines for
patient care.
The involvement of HCP will
depend on the Governance of
the network
Discussion of individual
clinical cases could be
proposed but the
maintenance will be a
challenge.
ICT tools will depend on
available funding.
Most HCPs identified are from
Western European countries.
Efforts should be done to
include more HCP from East
European countries.
++
The specialization of the
network should enable the
creation of formally accepted
professionalized guidelines for
patient care. One of the key
function of the ERNs is to
standardize care treatment,
and the involvement of HCP
directly connected to patients
will ensure the direct
translation of improved
treatments.
A forum for discussion of
individual clinical cases will be
proposed.
ICT-tools could be developed
to provide care, access to
expertise, and support the
development, sharing and
spread of best practice. (E.g.
Telemedicine, tele-expertise or
remote consultation).
Most HCPs identified are from
Western European countries.
Efforts should be done to
include more HCP from East
European countries.
The network complies with
the legal framework of the EC
in providing Health Care.
The role and involvement of
patients within the network








training are currently being
conducted (seminar, scientific
meeting, conferences...).
They are very close to the
professional needs, as
facilitated by the exchange
and informal atmosphere.
+
These activities would be very
close to the professionals
needs, and targeted to a very
specific field. Depending on
the resources available, they
will be implemented more
easily.
++
These activities would very
close to the professionals
needs, and facilitated by the
exchange of information on
the official online platforms.
Patients’ education material
are promoted by ERN.
Training and educational
activities are limited or not






already contribute to research




The creation of the network
itself is part of an R&I process.
The founders will need to
decide the relevance of the
research for the activities of
the network.
+ to ++
The main objective of the
ERNs is to improve healthcare
services, and the research
activities, although secondary,
are encouraged through the
consortium, and the
individuals.
Time is a constraint for
clinicians involved.
If external funding to fund
research is needed.
The amount of time to be








promote the exchange of
good practices, it is not
+
Through the formalisation of
the network, a set of outcome
measures and monitoring
++
ERNs are monitored and
controlled by both the HCP
and the funder (DG-Sante). A
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Table 2 Assessment of the three options for a potential network o rare Communicable diseases linked to Mobility and Globalisation
(Continued)
Maintaining Status Quo Creation of a European
expert network (EEN)
Creation of a new ERN
(ERN)




mandatory to follow up and
monitor the concrete impact




improve the health care
provision have been already
implemented (e.g. EVDLabNet
laboratory capacity sharing or
TROPNET – information access
to Orphan drugs).
There is not a defined quality
control planning with clear
objectives and measurable
indicators for monitoring and
evaluation, particularly
regarding the compliance of
the access to medical records
and clinical information with
the EU regulations.
should be set, and agreed by
the founders, especially to
justify costs and impact, and
obtain funding for their
activities.
However, to assure the
compliance of the access to
medical records and clinical
information with the EU
regulations will be challenge
to create and maintain a
system to assure the
confidentiality.
The network could also create
a standard procedure for
obtaining consent form.
series of Key Performance
Indicators (KPI) have to be
established, and their
outcomes and impact is
measured.
ERN requires a quality control
planning with clear objectives
and measurable indicators for
monitoring and evaluation,
particularly regarding the
compliance of the access to
medical records and clinical
information with the EU
regulations.
The network would also
create a standard procedure




The existing networks have a
very open approach towards
multidisciplinary collaboration,
particularly EuroTravNet.
No clear rules within the
networks on the openness
towards other disciplines is
established.
?
The founders will need to
decide the relevance given to
multi/trans-disciplinary
approach, within the scheme




ERN will ensure a
multidisciplinary approach to
treat the diseases/ affectations
at the core of the network.
There is also 24 other ERNs,
which meet and exchange at
least on a bi-annual basis,
summing up to the concrete
specificities of each one of
them.
Explore how to add social







collaboration is well engaged,
both within and towards
other networks, it is necessary
to establish it specifically on
Health Care Provision.
No official collaborations with
other disciplines have been
established (blood banks,
transplant or antenatal care
units among other).
+





would have to be developed.
+ to ++
The general networking and
collaborations towards
external players would have
to be developed.
However, collaboration with
other ERNs may be facilitated
through the ERN structure.
Define better priority lines of
collaboration.
Funding and sustainability criteria
Funding sources 0 to +
Networks are already
functioning, although with
low or non - financial
resources.




funded by private institutions
(International Society of Travel




TROPNET is not funded.
?
Important funding is needed
to create a network.
The feasibility is very much
depending if a special
funding line is put in place to
support the new structure or





To start the activities, an ERN
could receive resources from
EU Health programme.
A call for a new ERN would
provide the necessary funding
to start the activity.
Funding sources need to be
available in order to start
new activities, or consolidate
those already existing.
Sustainability 0 to + ? + to ++ Define the basis of self-
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necessarily recognised by the national health care
systems.
2. A EEN would have the benefit of being created
based on the findings and detected needs. Focus
would be Health Care provision, and areas and
diseases to be included would be the ones identified
as rare diseases linked to mobility and globalisation.
However, implementing a good system for data
registry or discussion of clinical cases would be
challenging in terms of sustainability. In addition,
there is not a clear mechanism to guarantee the
establishment of the EEN supported by the EC, and
also the general networking and collaborations with
external players would have to be developed.
Finally, funding is needed and sources have to be
identified, also in order to sustain the network,
particularly if a special funding line is not put in
place to support the new structure.
3. The basis and the legal status for an ERN have
already been established. Governance is a complex
aspect for ERNs [26]. Health Care Provision and
specialized care status is decided by national health
authorities and the participation and enrolment of
centres are decided at national level [5]. The areas
and diseases covered would be based on the
detected needs. The current ERNs are supported
with technological tools and online platforms
facilitating the safe and ethically acceptable
exchange of data, including the registries of cases. A
call for a new ERN would provide the necessary
funding to start the activity. Sustainability is a key
aspect of the ERNs, although the experience is too
recent to have a thorough model.
Discussion
Providing highly specialised diagnosis, treatment and
care for patients who have complex diseases can be a
challenge [27]. This is especially true when the
prevalence of such diseases is low, or when a new dis-
ease is emerging as is the case for rare diseases linked to
mobility and globalisation. This challenge is due both to
the scarcity of expertise and to the scattering of small
patient populations across the EU, sometimes in isolated
locations where expertise does not exist or cannot be
accessed. As a way of example, the evolution of the
COVID-19 pandemic is affecting the European Member
States (EU MS) with different levels of severity and with
an epidemiological situation is evolving very quickly
[28]. Although it is not a rare disease anymore in Eur-
ope, and the level of knowledge is similar in all EU
countries, it is a novel emerging disease unknown for
most health professionals and to establish a proper sys-
tem for sharing information and to establish potential
collaborations across countries would be highly valuable.
Many patients are in the need of highly specialised
care in third level hospitals. The practical experience on
how to manage the patients and in particular the severe
cases is scarce and scattered in Europe [27]. While the
experience and the number of cases treated by some
Hospitals (and MS) is important, due the accumulated
expertise, other are still starting to deal with complex
patients. Following the previous example, the treatments
applied to the COVID-19 patients are in many cases ex-
perimental and there are some limitations to reach the
knowledge generated during the last months and weeks.
Therefore, a new ERN could help to integrate the ex-
pertise and competence of those that have already have
them with the healthcare professionals that are directly
in charge of the patients by facilitating a quick exchange
of knowledge and experiences and assisting in the deci-
sion making process and ultimately to benefit the pa-
tients suffering the condition [27].
A European network on rare CD linked to mobility
and globalisation may provide a unique opportunity for
clinicians to work across borders in EU/EEA countries
in healthcare provision in order to tackle this challenge.
Table 2 Assessment of the three options for a potential network o rare Communicable diseases linked to Mobility and Globalisation
(Continued)
Maintaining Status Quo Creation of a European
expert network (EEN)
Creation of a new ERN
(ERN)




For now, networks have been
sustainable, as shown on their
existence overtime, and some
key collaborations or merger
are sought for.
It is unclear though how
sustainability is foreseen over
time if networks wish to grow
and to strengthen the
activities focused on Health
Care Provision.
To ensure sustainability
should be part of the basis of
the new network. If there is a
possibility to get the funds, a
sustainability strategy should
be put in place, through the
engagement of the partners.
Sustainability is a key aspect
of the ERNs, although for
now, the experience is too
recent to have a concrete
model (publicly funded,
through European or National
schemes) that can be
replicated for this new ERN.





tiple funders, but also
through clear and set en-
gagement of the stakeholders
involved.
Full note: In the assessment of each scenario, each criterion was rated once for the overall network. Each criterion has been graded in the following way: “0” The
scenario proposed does not fulfil the criterion; “+” The scenario proposed fulfil the criterion with limitations; “++” The scenario proposed fulfils the criterion; “?”
Difficult to assess, (for the variables and knowledge limitations on the aspects assessed)
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Coordination strategies among EU/EEA countries to
fight against new emerging communicable diseases may
be facilitated if there is a network oriented to improve
the diagnosis capacity and treatment options for patient
and learning from health professional experiences from
EU/EEA countries where the diseases have progressed
first. The network could also be well aligned with other
European initiatives or programmes in place on commu-
nicable diseases such as the ECDC associated networks,
or the One Health European Joint Programme without
overlapping or eclipsing any function or role of such
programmes or initiatives.
On the other hand, the study has several limitations
that need to be recognized. First, the heterogeneity of
the access to health care provision for individuals at risk
of mobility associated infectious diseases across EU
countries has not been properly evaluated. This is of
particular importance for undocumented migrants who
have restrictive access to health care services. This elem-
ent needs to be considered and evaluated when the net-
work is implemented. Second, the connection with other
initiatives or programmes with common objectives at
national and also at EU level need to be better evaluated
to be complementary instead of overlapping activities.
Finally, the sustainability of is a key aspect as per the rest
of ERN that need a widespread assessment although for
now, the experience of ERNs is too recent to have a con-
crete model.
Conclusions
If the focus is the health care provision, it could be con-
cluded that an ERN could have the potential to better
boost the quality of care. However, current existing net-
works should not be eclipsed by a potential new network
and they should be complementary. Future steps should
explore the Member states view and discussion on the
appropriateness for launching a new ERN.
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